Skip to content
Screener

Prime Medicine PRME Business Segments — Research costs

Similar metrics at other companies

Bicara Therapeutics logo
BCAXReportable Segment — Research
$601K+8.1%
ImmunityBio, Inc. logo
IBRXReportable Segment — Other research and development costs
$8.47M+31.0%
Globus Medical logo
GMEDReportable Segment — Research and Development Employee Related Costs
$26.13M-13.2%
Biogen logo
BIIBReportable Segment — Research and development:
$167.1M-0.7%
Viridian Therapeutics, Inc. logo
VRDNReportable Segment — Segment research and development expense
$64.19M-21.1%
Coursera logo
COURReportable Segment — Segment content costs
$84.4M+26.0%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$43.3M+18.9%
Net income-$42.1M+19.9%
EPS (diluted)-$0.24+41.5%

Balance sheet

See full
Cash & equivalents$61.1M-9.4%
Total debt$112.5M-6.1%
Total equity$39.8M-34.6%
Total assets$249.0M-10.7%

Cash flow

See full
Operating cash flow-$41.0M+0.9%
CapEx$46.0K-97.1%
Free cash flow-$41.1M+4.4%

Valuation

See full
Market cap$558.64M-10.7%
Enterprise value$609.98M-10.0%

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-373.3%-1,281pp
Debt / equity2.8×+0.9×
Current ratio3.1×-0.5×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept prme:ResearchAndDevelopmentExpenseResearchCosts.

The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:03 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053883
(in thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development expenses
Personnel expenses10,80014,44821,85329,248
Facility related10,57713,76520,84324,734
Research costs6,1588,11613,41819,152
General and administrative expenses:
Personnel expenses5,5597,08211,09114,238
Other segment items (1)11,34511,08128,74420,966
Total operating expenses44,43954,49295,949108,338

Item 1. Financial Statements (unaudited)

FAQ

What is Prime Medicine's business segments — research costs?
Prime Medicine (PRME) reported business segments — research costs of $6.16M in Q2 2026.
How has Prime Medicine's business segments — research costs changed year-over-year?
Prime Medicine's business segments — research costs decreased by 24.1% year-over-year, from $8.12M to $6.16M.
What is the long-term trend for Prime Medicine's business segments — research costs?
Over 2 years (2023 to 2025), Prime Medicine's business segments — research costs has grown at a -22.9% compound annual growth rate (CAGR), from $59.61M to $35.45M.
What does business segments — research costs mean?
Represents the expenditures dedicated to research and development activities within a specific business segment, aimed at discovering or advancing new technologies and products. This metric is critical for biotechnology companies, as it reflects the level of investment in the innovation pipeline and future growth potential. High spending in this area indicates a commitment to long-term product development and technological leadership.

Ask your AI about Prime Medicine's business segments — research costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude